New insights into uric acid effects on the progression and prognosis of chronic kidney disease

Renal Failure

Volumn 34, Issue 4, 2012, Pages 510-520

  Filiopoulos, Vassilis ^a   Hadjiyannakos, Dimitrios ^a   Vlassopoulos, Dimosthenis ^a  

^a AMALIA FLEMING GENERAL HOSPITAL   (Greece)

Author keywords

Arterial hypertension; Chronic kidney disease; Hyperuricemia; Renal disease progression; Uric acid

Indexed keywords

ALLOPURINOL; ARGININE; ATENOLOL; BENZIODARONE; ENALAPRIL; LOSARTAN; OTERACIL; URATE OXIDASE; URIC ACID;

ARTERIAL PRESSURE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; URIC ACID BLOOD LEVEL;

ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; HYPERURICEMIA; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RISK FACTORS; URIC ACID;

EID: 84859626188     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.653753     Document Type: Review

References (86)

1. Davies Jr NS. The cardiovascular and renal relations and manifestations of gout. J Am Med Assoc. 1897;29:261.
2. Nakagawa T, Kang DH, Feig D, et al. Unearthing uric acid: An ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int. 2006;69:1722-1725. (Pubitemid 43739197)
3. Mahomed FA. On chronic Bright's disease and its essential symptoms. Lancet. 1879;1:399-401.
4. Haig A. On uric acid and arterial tension. BMJ. 1889;1: 288-291.
5. Huchard H. Arteriolosclerosis: Including its cardiac form. J Am Med Assoc. 1909;53:1129-1132.
6. Berger L, Yü T. Renal function in gout: An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med. 1975;59:605-613.
7. Talbot JH, Terplan KL. The kidney in gout. Medicine. 1960;39:405-467.
8. Gonick HC, Rubini MD, Gleason IO, Sommers SC. The renal lesion in gout. Ann Int Med. 1965;62:667-674.
9. Beck L. Requiem for gouty nephropathy. Kidney Int. 1986;30:280-287. (Pubitemid 16046971)
10. Johnson RJ, Kivlighn SD, Kim Y-G, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular and renal disease. Am J Kidney Dis. 1999;33:225-234. (Pubitemid 29072223)
11. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? J Am Soc Nephrol. 2003;41:1183-1190. (Pubitemid 36706063)
12. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: Implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol. 2005;70:343-354. (Pubitemid 40905106)
13. Hink HU, Santanam N, Dikalov S, et al. Peroxidase properties of extracellular superoxide dismutase: Role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol. 2002;22:1402-1408.
14. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: A reaction to atherosclerosis? Atherosclerosis. 2000;148:131-139.
15. Filiopoulos V, Hadjiyannakos D, Metaxaki P, et al. Inflammation and oxidative stress in patients on hemodiafiltration. Am J Nephrol. 2008;28(6):949-957.
16. Nakagawa T, Mazzali M, Kang DH, Sanchez-Lozada LG, Herrara-Acosta J, Johnson RJ. Uric acid: A uremic toxin? Blood Purif. 2006;24:67-70.
17. Kang DH, Nakagawa T, Feng L, et al. A role of uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13: 2888-2897. (Pubitemid 35386908)
18. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid induced C-reactive protein (CRP) expression: Implication on cell proliferation and nitric oxide production in human vascular cells. J Am Soc Nephrol. 2005;16:3553-3562. (Pubitemid 46211276)
19. Waring WS, Webb DJ, Maxwell SRJ. Effect of local hyperuricemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol. 2000;49:511.
20. Glinsberg MH, Kozin F, O'Malley M, McCarty DJ. Release of platelet constituents by monosodium urate crystals. J Clin Invest. 1997;60:999-1007.
21. Feig D, Mazzali M, Kang DH, et al. Serum uric acid: A risk factor and a target for treatment? J Am Soc Nephrol. 2006;17:69-73.
22. Feig D, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Eng J Med. 2008;359:1811-1821.
23. Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension. The Olivetti heart study. J Hum Hypertens. 1994;8:677-681. (Pubitemid 24276965)
24. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. J Am Med Assoc. 2000;283:2404-2410. (Pubitemid 30257539)
25. Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men. The Osaka Health Survey. J Hypertens. 2001;19:1209-1215. (Pubitemid 32595276)
26. De Leeuw PW, Thijs L, Birkenhäger WH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: Results from the Syst-Eur Trial. J Am Soc Nephrol. 2002;13:2213-2222. (Pubitemid 34925231)
27. Bickel C, Rupprecht HJ, Blankenberg S, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89:12-17. (Pubitemid 34066579)
28. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474-480. (Pubitemid 37237341)
29. Nakanishi N, Okamato M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and the risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18: 523-530. (Pubitemid 36899556)
30. Sundstrom J, Sullivan L, D'Agostino R, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension. 2005;45:28-33. (Pubitemid 40066409)
31. Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular and death: The Framingham Heart Study. Ann Intern Med. 1999;131:7-13. (Pubitemid 29310011)
32. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WE. Serum uric acid and risk of coronary heart disease: Atherosclerosis risk in communities (ARIC) Study. Ann Epidemiol. 2000;10:136-143. (Pubitemid 30171270)
33. Navaneethan SD, Beddhu S. Associations of uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol Dial Transplant. 2009;24:1260-1266.
34. Neri L, Rocca Rey LA, Lentine KL, et al. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: A historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis. 2011;58:398-408.
35. Kahn HA, Medalie JH, Neufeld HN, Riss E, Goldbourt U. The incidence of hypertension and associated factors: The Israel ischemic heart study. Am Heart J. 1972;84:171-182.
36. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275:457-464.
37. Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HA. Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med. 1973;132:401-410.
38. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med. 1988;85:134-138.
39. Pearson T, Blair S, Daniels S, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388-391. (Pubitemid 34778969)
40. Chobanian A, Bakris G, Black H, et al. National Heart, Lung, and Blood Institute; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. J Am Med Assoc. 2003;289:2560-2572.
41. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystalindependent mechanism. Hypertension. 2001;38:1101-1106. (Pubitemid 34252813)
42. Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol. 2007;18:287-292. (Pubitemid 46053441)
43. Kaplan NM, Opie LH. Controversies in hypertension. Lancet. 2006;367:168-176. (Pubitemid 43077131)
44. Johnson RJ, Feig DI. Hyperuricemia in childhood essential hypertension. Hypertension. 2003;42:247-252.
45. Silverstein DM, Srivaths PR,Mattison P, et al. Serum uric acid is associated with high blood pressure in pediatric hemodialysis patients. Pediatr Nephrol. 2011;26:1123-1128.
46. Tseng CH. Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney Int. 2005;68:796-801.
47. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Hypouricemia and hyperuricemia in type 2 diabetes: Two different phenotypes. Eur J Clin Invest. 2001;31: 318-321. (Pubitemid 32328532)
48. Syrjänen J, Mustonen J, Pasternak A. Hypertriglyceridemia and hyperuricemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant. 2000;15:34-42. (Pubitemid 30037928)
49. Ohno I, Hosoya T, Gomi H, Ichida K, Okabe H, Hikita M. Serum uric acid and renal prognosis in IgA nephropathy. Nephron. 2001;87:333-339. (Pubitemid 32260834)
50. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691-697. (Pubitemid 33133783)
51. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44: 642-650. (Pubitemid 39237608)
52. Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a Southeast Asian population: A 12-year cohort study. J Am Soc Nephrol. 2005;16:791-799. (Pubitemid 41725116)
53. Ishani A, Grandits GA, Grimm RH, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol. 2006;17:1444-1452. (Pubitemid 43673426)
54. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461-470. (Pubitemid 29135798)
55. Conchol MB, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50:239-247. (Pubitemid 47095076)
56. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19:1204-1211.
57. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19: 2407-2413.
58. Ben-Dov IZ, Kark JD. Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: The Jerusalem Lipid Research Clinic cohort study. Nephrol Dial Transplant. 2011;26:2558-2566.
59. Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53:796-803.
60. Sturm G, Kollerits B, Neyer U, Ritz E, Kronemberg F, MMKD Study Group. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2008;43:347-352.
61. Mohandas R, Johnson RJ. Uric acid levels increase risk for newonset kidney disease. J Am Soc Nephrol. 2008;19:2251-2253.
62. Bradley A, Caskey CT. Hyperuricemia and urate nephropathy in urate oxidase deficient mice. Proc Natl Acad Sci USA. 1994;91:742-746. (Pubitemid 24041478)
63. Nakagawa T, Mazzali M, Kang DH, et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol. 2003;23:2-7. (Pubitemid 35316757)
64. Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis salt-sensitivity. Hypertension. 2002;40:355-360. (Pubitemid 35006723)
65. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med. 2002;346:913-923. (Pubitemid 34984641)
66. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282:F991-F997. (Pubitemid 34654464)
67. Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67:237-247. (Pubitemid 40019245)
68. Mazzali M, Kim Y-G, Suga S, et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation. 2001;71:900-905. (Pubitemid 32417351)
69. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Fructoseinduced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol. 2005;1: 80-86.
70. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290:F625-F631. (Pubitemid 43724964)
71. Cirillo P, Sato W, Reungjui S, et al. Uric acid, the metabolic syndrome and renal disease. J Am Soc Nephrol. 2006;17: 165-168.
72. Taalat KM, El-Sheikh AR. The effect of mild hyperuricaemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27:435-440. (Pubitemid 47481999)
73. Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricaemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39:1227-1233. (Pubitemid 350193621)
74. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51-59. (Pubitemid 41828266)
75. Afshari M, Larijani B, Rezaie A, et al. Ineffectiveness of allopourinol in reduction of oxidative stress in diabetic patients; A randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother. 2004;58:546-550. (Pubitemid 40260375)
76. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000;35:746-751. (Pubitemid 30165320)
77. Kao MP, Ang DS, Gandy SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011;22:1382-1389.
78. Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid in cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65(3):1041-1049. (Pubitemid 38251080)
79. Miao Y, Ottenbros SA, Laverman GD, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulindependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011;58:2-7.
80. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388-1393.
81. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25-32. (Pubitemid 350298142)
82. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure in adolescents with newly diagnosed essential hypertension: A randomized trial. J Am Med Assoc. 2008;300(8):924-932.
83. Neal DA, Tom BD, Gimson AE, et al. Hyperuricemia, gout and renal function after liver transplantation. Transplantation. 2001;72:1689-1691. (Pubitemid 33096748)
84. Saglam F, Celic A, Sarioglu S, et al. Hyperuricemia influences chronic cyclosporine nephropathy. Transplant Proc. 2008;40(1):167-170. (Pubitemid 351186614)
85. Akalin E, Ganeshan SV,Winston J, Muntner P. Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation. 2008;86(5):652-658.
86. Ejaz AA, Mu W, Kang DH, et al. Could uric acid have a role in acute renal failure? Clin J Am Soc Nephrol. 2007;2:16-21.